Cover Image
市場調查報告書

亞太地區的大腸癌症治療藥市場:隨著域內的就醫率改善,高成本的標靶治療也有普及的動向

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies

出版商 GBI Research 商品編碼 318827
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的大腸癌症治療藥市場:隨著域內的就醫率改善,高成本的標靶治療也有普及的動向 Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies
出版日期: 2014年10月31日 內容資訊: 英文 100 Pages
簡介

亞太地區大腸癌症治療藥的市場規模,推算在2013年為19億美元,到2020年將達到29億美金,同時該期間的年複合成長率(CAGR)則將達到6.5%。為了確保區域內患者可得到高成本的治療方法,標的療法正在普及化,一般認為這將有助於今後市場的成長。此外,臨床實驗後期階段的開發中產品即將上市的動向,發病率的增加也是推動市場成長的要素。同時由於印度·中國的藥價限制和就醫率尚低,將是今後阻礙成長的要素。

本報告提供亞太地區各國的大腸癌症治療方法相關市場分析,提供疾病概要和主要的治療模式,已上市產品概要(安全性·功效等),現在開發中的治療藥之開發平台資訊,地區整體及主要國家的市場趨勢預測(今後8年的預測值),資本交易·產業聯盟的動向等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 大腸癌症
  • 症狀
  • 流行病學
  • 病理學
    • 組織學
    • 遺傳學的基材
    • 病因
  • 診斷
    • 數位式直腸檢驗
    • 大便潛血試驗
    • 軟式乙狀直腸鏡檢驗
    • 大腸內視鏡檢驗
    • 虛擬大腸鏡檢查內視鏡檢驗
    • 雙重造影灌腸
  • 預後和分期
  • 治療選擇
    • 外科手術·放射治療
    • 化療
    • 標靶治療
    • 對藥物療法的抗拒
    • 治療指南

第3章 已上市產品

  • 主要的已上市產品
    • 免疫療法
    • 標靶治療
  • 腹腔內溫熱化療(Hyperthermic Intraperitoneal Chemotherapy)
  • 已上市產品的熱圖

第4章 開發平台分析

  • 整體開發平台
    • 開發平台分析:各分子類型
    • 開發平台分析:運作機制別
  • 臨床實驗
    • 失敗率
    • 臨床實驗的規模
    • 臨床實驗期間
  • 開發平台上的有潛力候補藥
    • Lonsurf(TAS-102(chipirashiru+torifururijin):大鵬藥品工業)
    • Cyramza - ramushirumabu:Eli Lilly and Company
    • TS-1/Teysuno(tegafuru+gimerashiru+oterashiru):大鵬藥品工業
    • CPP-1X(鹽酸efurorunichin)+surindaku:Cancer Prevention Pharmaceuticals
    • MelCancerVac:DanDrit Biotech
    • Xilonix:XBiotech
    • nintedanibu:Boehringer Ingelheim

第5章 市場未來預測

  • 亞太地區市場
    • 治療藥的使用模式
    • 市場規模
  • 澳洲
    • 治療藥的使用模式
    • 年度治療費用
    • 市場規模
  • 印度
  • 中國
  • 日本
  • 市場促進·阻礙因素

第6章 資本交易及策略性企業整合

  • 授權合約
    • 主要的許可證交易
  • 共同開發契約
    • 主要的共同開發契約

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $2.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes -

  • A brief introduction to CRC, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Colorectal Cancer
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Pathophysiology
    • 2.4.1. Histology
    • 2.4.2. Genetic Basis
    • 2.4.3. Etiology
  • 2.5. Diagnosis
    • 2.5.1. Digital Rectal Examination
    • 2.5.2. Fecal Occult Blood Test
    • 2.5.3. Flexible Sigmoidoscopy
    • 2.5.4. Colonoscopy
    • 2.5.5. Virtual Colonoscopy
    • 2.5.6. Double Contrast Barium Enema
  • 2.6. Prognosis and Disease Staging
  • 2.7. Treatment Options
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Chemotherapy
    • 2.7.3. Targeted Therapies
    • 2.7.4. Resistance to Pharmacological Therapies
    • 2.7.5. Treatment Guidelines

3. Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Immunotherapies
    • 3.1.2. Targeted Therapies
  • 3.2. Hyperthermic Intraperitoneal Chemotherapy
  • 3.3. Heat Map for Marketed Products

4. Pipeline Analysis

  • 4.1. Overall Pipeline
    • 4.1.1. Pipeline Analysis by Molecule Type
    • 4.1.2. Pipeline Analysis by Mechanism of Action
  • 4.2. Clinical Trials
    • 4.2.1. Failure Rate
    • 4.2.2. Clinical Trial Size
    • 4.2.3. Duration
  • 4.3. Promising Drug Candidates in Pipeline
    • 4.3.1. Lonsurf (TAS-102(tipiracil. trifluridine)). Taiho Pharmaceutical
    • 4.3.2. Cyramza. ramucirumab. Eli Lilly and Company
    • 4.3.3. TS-1/Teysuno (tegafur. gimeracil. oteracil). Taiho Pharmaceutical
    • 4.3.4. CPP-1X (eflornithine hydrochloride). sulindac. Cancer Prevention Pharmaceuticals
    • 4.3.5. MelCancerVac. DanDrit Biotech
    • 4.3.6. Xilonix. Xbiotech
    • 4.3.7. Nintedanib. Boehringer Ingelheim

5. Market Forecast to 2020

  • 5.1. Asia-Pacific Market
    • 5.1.1. Treatment Use Patterns
    • 5.1.2. Market Size
  • 5.2. Australia
    • 5.2.1. Treatment Use Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. India
    • 5.3.1. Treatment Use Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Use Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Use Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Asia-Pacific
    • 7.2.2. Australia
    • 7.2.3. India
    • 7.2.4. China
    • 7.2.5. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. References for Heat Map
  • 7.7. Research Methodology
    • 7.7.1. Coverage
    • 7.7.2. Secondary Research
    • 7.7.3. Primary Research
    • 7.7.4. Therapeutic Landscape
    • 7.7.5. Geographical Landscape
    • 7.7.6. Pipeline Analysis
  • 7.8. Expert Panel Validation
  • 7.9. Contact Us
  • 7.10. Disclaimer

List of Tables

  • Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013
  • Table 2 Surgical Options for Colorectal Cancer
  • Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
  • Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
  • Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2013
  • Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
  • Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
  • Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
  • Table 9 Colorectal Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013-2020
  • Table 10 Colorectal Cancer Therapeutics, Australia, Forecast Data, 2013-2020
  • Table 11 Colorectal Cancer Therapeutics, India, Forecast Data, 2013-2020
  • Table 12 Colorectal Cancer Therapeutics, China, Forecast Data, 2013-2020
  • Table 13 Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013-2020
  • Table 14: Colorectal Cancer Market, References for Heat Map

List of Figures

  • Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III)
  • Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV)
  • Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products)
  • Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013
  • Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013
  • Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2013
  • Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013
  • Figure 10: Colorectal Cancer Therapeutics, Asia-Pacific, Treatment Use Patterns ('000) ,2013-2020
  • Figure 11: Colorectal Cancer Therapeutics, Asia-Pacific, Market Size ($bn), 2013-2020
  • Figure 12: Colorectal Cancer Therapeutics, Australia, Treatment Use Patterns ('000), 2013-2020
  • Figure 13: Colorectal Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 2013-2020
  • Figure 14: Colorectal Cancer Therapeutics, Australia, Market Size ($m), 2013-2020
  • Figure 15: Colorectal Cancer Therapeutics, India, Treatment Use Patterns ('000), 2013-2020
  • Figure 16: Colorectal Cancer Therapeutics, India, Annual Cost of Therapy ($), 2013-2020
  • Figure 17: Colorectal Cancer Therapeutics, India, Market Size ($m), 2013-2020
  • Figure 18: Colorectal Cancer Therapeutics, China, Treatment Use Patterns ('000), 2013-2020
  • Figure 19: Colorectal Cancer Therapeutics, China, Annual Cost of Therapy ($), 2013-2020
  • Figure 20: Colorectal Cancer Therapeutics, China, Market Size ($m), 2013-2020
  • Figure 21: Colorectal Cancer Therapeutics, Japan, Treatment Use Patterns ('000), 2013-2020
  • Figure 22: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 23: Colorectal Cancer Therapeutics, Japan, Market Size, 2013-2020
  • Figure 24: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006-2014
  • Figure 25: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006-2014
  • Figure 26: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006-2014
  • Figure 27: GBI Research Market Forecasting Model
Back to Top